Program
XMAB412
A development code. Also written as “XmAb412 Monoclonal Bispecific Antibody”.
Its studies are mostly in Inflammatory Bowel Diseases, led by Xencor.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xencor | 11 open or running | phase 1since Jul 14, 2026 | Jul 14, 2026 | Aug 2027phase 1 · NCT07713485 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2026First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT07713485 · 128 planned · Australia
- Nov 12, 2026Primary completion moved from 2027-05 to 2027-08Date moved laterphase 1 · +3 months · NCT07713485
Ahead
- Aug 2027Primary completion: phase 1 study in Inflammatory Bowel DiseasesNCT07713485
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07713485Inflammatory Bowel Diseases · Australia | 1 | Recruiting | Aug 2027 | 128 |
How it is read
Names in the registry
- “XmAb412 Monoclonal Bispecific Antibody”, 1 entry
Codes read as this program: XMAB412.
Conditions, from the studies’ own filings
- Inflammatory Bowel Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.